Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings
Moderna experienced a record-breaking 101% intraday surge after announcing that its personalized cancer vaccine, combined with Merck's Keytruda, significantly reduced melanoma recurrence in a late-stage trial and met secondary goals for preventing tumor spread. In other market moves, Estee Lauder rallied on better-than-expected earnings and guidance, while La-Z-Boy declined after missing sales forecasts for the upcoming quarter.
1 Article
Trace's outlet lean is shown first — tap Left / Center / Right on each source to add your rating too.
- BloombergTrace: Center
Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers
Moderna experienced a record-breaking 101% intraday surge after announcing that its personalized cancer vaccine, combined with Merck's Keytruda, significantly reduced melanoma recurrence in a late-stage trial and met secondary goals for preventing tumor spread. In other market moves, Estee Lauder rallied on better-than-expected earnings and guidance, while La-Z-Boy declined after missing sales forecasts for the upcoming quarter.
Rate outletRead original